A new class of injectable therapies for hemophilia A has fundamentally changed what it means to live with the condition, replacing the grueling routine of daily or every-other-day intravenous factor VIII infusions with subcutaneous shots given as infrequently as once every two months. The most recent arrival, Qfitlia (fitusiran), earned FDA approval on March 28, 2025, and uses small interfering RNA technology to reduce bleeding episodes by more than 70 percent with just six injections per year. For the estimated 30,000 to 33,000 Americans living with hemophilia — and the families and caregivers who help manage their treatment — this shift away from constant venous access represents one of the most meaningful quality-of-life advances in decades. The relevance to brain health and dementia care may not be immediately obvious, but it matters.
Older adults with hemophilia face a heightened risk of intracranial hemorrhage, a catastrophic event that can cause vascular dementia, lasting cognitive impairment, or death. Caregivers of hemophilia patients who also have cognitive decline shoulder a uniquely difficult burden when treatment requires frequent IV infusions, sterile technique, and careful vein management. Simpler dosing schedules — a subcutaneous pen rather than an IV line — can be the difference between manageable home care and institutional placement. This article walks through the new injectable options now available, how each one works, what the clinical data actually show, the real-world tradeoffs of cost and access, and what caregivers and patients should weigh when discussing these treatments with their hematology teams.
Table of Contents
- How Do New Injectables for Hemophilia A Eliminate the Need for Daily Factor Replacement?
- Qfitlia (Fitusiran) — What Six Injections Per Year Actually Mean in Practice
- Hemlibra and Alhemo — The Subcutaneous Options Already on the Market
- Comparing Treatment Schedules and What Caregivers Should Weigh
- The Cost Reality and Access Barriers That Complicate These Advances
- Why Brain Health Providers Should Know About These Treatments
- What Comes Next in Hemophilia Treatment
- Conclusion
- Frequently Asked Questions
How Do New Injectables for Hemophilia A Eliminate the Need for Daily Factor Replacement?
Traditional hemophilia A treatment works by directly replacing the missing clotting factor VIII through intravenous infusion. Because standard factor VIII products have short half-lives — they fall below protective levels within about two days — patients on prophylaxis have historically needed IV infusions every one to two days. That means finding a vein, setting up supplies, and spending 20 to 45 minutes on an infusion multiple times per week. For a person with advancing cognitive decline, or for a caregiver already managing medication schedules and behavioral symptoms, that frequency is unsustainable. The newer injectables sidestep this problem by targeting different parts of the clotting cascade rather than simply pouring more factor VIII into the bloodstream. Qfitlia degrades antithrombin mRNA in liver cells, reducing the natural anticoagulant antithrombin and allowing the body to generate more thrombin on its own. Hemlibra, approved back in 2017, is a bispecific antibody that mimics factor VIII’s bridging function.
Alhemo blocks tissue factor pathway inhibitor to enhance factor Xa production. None of these require venous access. They are all subcutaneous — a quick shot under the skin, similar to an insulin injection. The practical comparison is stark. A patient on standard factor VIII might receive 150 to 180 IV infusions per year. A patient on Hemlibra can get by with 13 to 52 subcutaneous injections annually, depending on the dosing schedule. A patient on Qfitlia may need as few as six. For someone whose cognitive function is declining and whose veins are increasingly fragile from age and repeated access, that reduction is not a minor convenience — it is a clinical necessity.
Qfitlia (Fitusiran) — What Six Injections Per Year Actually Mean in Practice
Qfitlia’s approval marked a genuine first: the only small interfering RNA therapy for hemophilia. Its mechanism is elegant but unfamiliar to most patients and caregivers. Rather than replacing or mimicking clotting factor, fitusiran silences the gene that produces antithrombin, a protein the liver makes to prevent excessive clotting. By lowering antithrombin levels into a controlled range of 15 to 35 percent activity, the drug tips the hemostatic balance back toward adequate clot formation. The starting dose is 50 milligrams subcutaneously once every two months, adjusted over time using a companion diagnostic blood test. The Phase 3 ATLAS trials showed a 71 percent reduction in annualized bleeding rate among patients without inhibitors compared to on-demand factor treatment, dropping from 31.4 bleeds per year to 9.0.
For patients with inhibitors — a subset that has historically been the hardest to treat — the reduction was 73 percent. These are meaningful numbers, but they come with an important caveat: Qfitlia is currently approved only for adults and pediatric patients aged 12 and older. Younger children, who represent a significant portion of newly diagnosed hemophilia patients (roughly 400 babies per year in the United States are born with hemophilia A), are not yet covered. There is also a monitoring requirement that standard factor replacement does not carry. Because Qfitlia works by suppressing a natural anticoagulant, there is a theoretical and observed risk of thrombotic events if antithrombin levels drop too low. Patients must have regular blood draws to keep levels in the target range. For a dementia caregiver managing an older adult with hemophilia, this means fewer infusion days but continued lab appointments — a tradeoff worth understanding before assuming the treatment is entirely hands-off.
Hemlibra and Alhemo — The Subcutaneous Options Already on the Market
Before Qfitlia arrived, Hemlibra (emicizumab) had already reshaped hemophilia A treatment. Approved in 2017 by Roche, it is now the number one treatment option for hemophilia A prophylaxis worldwide. The drug is a bispecific antibody that bridges clotting factors IXa and X, performing the same job that factor VIII would in a healthy person. Dosing is flexible: after a loading phase of 3 milligrams per kilogram weekly for four weeks, patients can choose maintenance schedules of weekly, every two weeks, or every four weeks — all subcutaneous. For a caregiver coordinating care, the every-four-weeks option means just 13 injections per year. Alhemo (concizumab), from Novo Nordisk, takes a different approach. This monoclonal antibody targets tissue factor pathway inhibitor, or TFPI, removing a natural brake on the clotting cascade.
Originally approved in December 2024 for hemophilia patients with inhibitors, the fda expanded its label in July 2025 to include patients without inhibitors. The clinical results from the explorer8 Phase 3 trial were striking: an 86 percent reduction in annualized bleeding rate for hemophilia A patients without inhibitors and the same 86 percent reduction for those with inhibitors. Those numbers compare favorably to every other option on the market. The tradeoff with Alhemo is frequency. It requires daily subcutaneous injections via a prefilled pen after an initial loading dose of 1 milligram per kilogram. Daily dosing is far simpler than IV infusion — it takes seconds rather than half an hour — but for a patient with moderate to advanced dementia who resists injections or cannot understand what is happening, daily needle sticks may still present challenges. Caregivers should discuss this honestly with the treatment team. The most common side effects in trials were injection site reactions and headaches, each occurring in about 7 percent of patients.
Comparing Treatment Schedules and What Caregivers Should Weigh
The decision among these therapies is not simply which one reduces bleeding the most. It involves weighing injection frequency, route of administration, monitoring requirements, and the patient’s cognitive and physical capacity to participate in their own care. Here is how the current options line up in practical terms. Altuviiio, approved in February 2023, extends the half-life of factor VIII itself through a fusion protein technology, achieving a half-life three to four times longer than standard products. It still requires intravenous infusion, but only once per week rather than every one to two days. Its clinical results were impressive — a mean annualized bleeding rate of just 0.70, representing a 77 percent reduction versus prior factor prophylaxis. For patients who still have good venous access and are comfortable with IV infusion, this may offer the best bleeding protection.
But for older patients with poor veins or cognitive impairment, IV access once a week may still be one time too many. Among the subcutaneous options, the tradeoffs break down roughly like this: Qfitlia offers the least frequent dosing at six times per year but requires lab monitoring and is approved only for ages 12 and up. Hemlibra offers flexible scheduling from weekly to monthly with a long track record and the broadest clinical experience. Alhemo provides the strongest bleeding reduction in trials at 86 percent but demands daily injections. There is no single best answer. A caregiver managing someone with early-stage cognitive decline and good self-injection skills might choose Alhemo for its efficacy. A caregiver managing someone with advanced dementia might prioritize Qfitlia’s every-two-month schedule or Hemlibra’s monthly option to minimize disruptive encounters. The conversation with the hematologist should center on the patient’s full picture, not just their bleeding history.
The Cost Reality and Access Barriers That Complicate These Advances
None of these therapies are inexpensive, and for families already strained by the costs of dementia care, the financial dimension cannot be ignored. Altuviiio carries a list price of roughly $625,000 per year for a patient requiring 1,000 international units per week, scaling up to as much as $1.8 million per year for patients needing 3,000 IU weekly. Sanofi priced it at parity with the annual cost of its older product Eloctate, but parity pricing for hemophilia drugs still means six- to seven-figure annual bills. Hemlibra, Qfitlia, and Alhemo all carry significant price tags as well, though manufacturer patient assistance programs and specialty pharmacy support exist for most. Insurance coverage varies widely.
Many commercial plans and Medicare Part B cover these products, but prior authorization requirements can delay treatment starts by weeks. For patients transitioning from one therapy to another — say, moving from twice-weekly factor VIII to Qfitlia — there can be gap periods where coverage for the new drug has not yet been approved while the old prescription has been discontinued. During these gaps, patients are unprotected against bleeds, including the intracranial hemorrhages that pose the greatest risk to brain health. Caregivers and families should work with their hemophilia treatment center’s social worker to ensure seamless transitions, and should never stop a current prophylactic regimen before the replacement therapy is confirmed and in hand. Hemlibra’s patent expires around 2032, and biosimilar competition is anticipated after that date. This could eventually lower costs for the most widely used subcutaneous option, but for the foreseeable future, these therapies remain among the most expensive medications in the pharmacy.
Why Brain Health Providers Should Know About These Treatments
Intracranial hemorrhage is the leading cause of death in people with hemophilia, and even non-fatal bleeds in the brain can produce lasting cognitive damage that mimics or accelerates dementia. A patient who presents to a memory clinic with progressive cognitive decline and a hemophilia diagnosis should prompt the care team to investigate whether bleeding events — including subclinical microbleeds — might be contributing to the picture. Adequate prophylaxis is neuroprotective in a very literal sense.
Neurologists, geriatricians, and dementia care specialists who encounter hemophilia patients in their practice should be aware that the treatment landscape has changed radically. If a patient or caregiver mentions struggling with IV infusions, it is worth asking whether they have discussed subcutaneous alternatives with their hematologist. Over 1.1 million people worldwide live with hemophilia, with 418,000 having a severe form, and many — particularly in lower-resource settings — remain undiagnosed or undertreated. Closing that gap has direct implications for brain health outcomes.
What Comes Next in Hemophilia Treatment
The pace of innovation in hemophilia care shows no signs of slowing. Gene therapy, which aims to provide a one-time functional cure by delivering a working copy of the factor VIII gene, has already seen its first approvals in recent years and is generating long-term follow-up data. If gene therapy proves durable, it could eventually make even the most convenient injectable regimens unnecessary for some patients.
In the nearer term, the competitive pressure among Qfitlia, Hemlibra, Alhemo, and Altuviiio is likely to drive improvements in dosing convenience, safety monitoring, and potentially pricing. Combination approaches — using a non-factor therapy as a baseline with on-demand factor for breakthrough bleeds — are being studied and refined. For caregivers and patients navigating hemophilia alongside cognitive decline, the trajectory is genuinely hopeful: less time tethered to IV poles, fewer disruptions to daily life, and better protection against the bleeds that threaten both body and brain.
Conclusion
The era of daily or every-other-day IV factor replacement as the only option for hemophilia A prophylaxis is over. Patients and caregivers now have access to subcutaneous therapies ranging from daily injections with Alhemo to bimonthly shots with Qfitlia, alongside the well-established weekly-to-monthly schedule of Hemlibra and the once-weekly IV option of Altuviiio. Each carries its own profile of efficacy, convenience, monitoring needs, and cost, but all represent a dramatic improvement over the treatment burden that defined hemophilia care for decades.
For those in the dementia care community — whether you are a caregiver, a clinician, or a patient managing both conditions — understanding these options matters. Simpler treatment regimens reduce caregiver strain, improve adherence, and protect against the intracranial bleeding events that can cause or worsen cognitive decline. If your current hemophilia treatment plan still revolves around frequent IV infusions, a conversation with a hemophilia treatment center about these newer alternatives is worth having now, not later.
Frequently Asked Questions
Can a person with dementia self-administer these subcutaneous hemophilia injections?
It depends on the stage of cognitive decline. In early stages, many patients can manage a prefilled pen injection with supervision. In moderate to advanced dementia, a caregiver or visiting nurse will need to administer the injection. The less frequent the dosing schedule, the more practical this becomes — Qfitlia’s six-times-per-year schedule is the easiest to manage with outside help.
Does hemophilia treatment affect dementia medications or vice versa?
The non-factor therapies like Hemlibra, Qfitlia, and Alhemo do not have known major interactions with common dementia medications such as cholinesterase inhibitors or memantine. However, any medication that affects platelet function or bleeding risk — including over-the-counter NSAIDs sometimes used for pain — should be discussed with both the hematologist and the neurologist.
Are these new hemophilia injectables available for patients with hemophilia B as well?
Yes, some of them. Qfitlia is approved for both hemophilia A and hemophilia B, with or without inhibitors. Alhemo is also approved for both types. Hemlibra, however, is approved only for hemophilia A because it specifically mimics factor VIII function. Altuviiio is likewise specific to hemophilia A.
What is the risk of intracranial hemorrhage in older adults with hemophilia?
It is the leading cause of death among people with hemophilia. Older adults face compounding risks because age-related vascular fragility combines with the underlying clotting deficiency. Adequate prophylaxis — whether with factor replacement or one of the newer non-factor therapies — significantly reduces this risk, which is why maintaining consistent treatment is critical for brain health.
How do inhibitors affect treatment choices for hemophilia A?
Inhibitors are antibodies that some hemophilia patients develop against infused factor VIII, rendering standard replacement therapy ineffective. Roughly 25 to 30 percent of severe hemophilia A patients develop inhibitors. The newer therapies are particularly valuable for this group: Qfitlia, Alhemo, and Hemlibra are all approved for patients with inhibitors, while Altuviiio is a factor VIII product and therefore not suitable for patients whose immune systems attack factor VIII.
